plazomicin Side Effects
Also known as: Zemdri
Analysis of 3 adverse event reports submitted to the FDA from 2021 to 2022.
Total Reports
3
Hospitalizations
1
33.3% of reports
Top Indication
Infusion
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Hospitalization Reports
Top reactions in 1 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| CREATININE RENAL CLEARANCE DECREASED | 1 |
| RENAL FAILURE | 1 |
Nearby — Related Medications
What the FAERS Data Reveals About plazomicin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 3 voluntary reports linked to plazomicin and its brand equivalents (Zemdri), spanning 2021 through 2022. No reports in this dataset listed death as an outcome and 1 (33.3%) involved hospitalization. The most common indication reported alongside adverse events was Infusion.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 0% were female and 100% male; age distribution skews toward 18-44, with 1 report in that bracket. The single most reported reaction is acute kidney injury with 1 submission, followed by antibiotic level above therapeutic and creatinine renal clearance decreased.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.